Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.

Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci. 2019 Nov 13;: Authors: Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina…

Read More

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.

Related Articles Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. Gastroenterology. 2019 Nov 08;: Authors: Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J Abstract BACKGROUND AND AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis (UC). METHODS: In a phase 2,…

Read More

DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN’S DISEASE BASED ON SERUM LEVELS OF PROTEINS.

Related Articles DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN’S DISEASE BASED ON SERUM LEVELS OF PROTEINS. Gastroenterology. 2019 Nov 08;: Authors: D’Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS Abstract BACKGROUND & AIMS: Non-invasive tests…

Read More

Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old or Obstetric.

Related Articles Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old or Obstetric. Clin Gastroenterol Hepatol. 2019 Nov 08;: Authors: Singh S, Picardo S, Seow CH Abstract The epidemiology of inflammatory bowel disease (IBD) is progressively evolving impacting the type of patients with IBD we will see in clinical practice. In this review, we discuss specific challenges and solutions in the management of (a) obese, (b) older and (c) obstetric (pregnant) patients with IBD. With the global obesity epidemic, almost one in three patients with IBD are obese. Obesity…

Read More

Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer.

Related Articles Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer. Dig Dis Sci. 2019 Nov 11;: Authors: Kim J, Feagins LA Abstract Prostate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to…

Read More

Biofeedback for treatment of irritable bowel syndrome.

Biofeedback for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2019 Nov 12;2019(11): Authors: Goldenberg JZ, Brignall M, Hamilton M, Beardsley J, Batson RD, Hawrelak J, Lichtenstein B, Johnston BC Abstract BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent condition that currently lacks highly effective therapies for its management. Biofeedback has been proposed as a therapy that may help individuals learn to exert conscious control over sympatho-vagal balance as an indirect method of symptom management. OBJECTIVES: Our primary objective was to assess the efficacy and safety of biofeedback-based interventions…

Read More

Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence.

Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 Nov 07;: Authors: Lei DK, Ollech JE, Andersen M, Weisshof R, Zmeter N, Sossenheimer P, Rubin DT Abstract OBJECTIVES: Patients with inflammatory bowel disease (IBD) are susceptible to Clostridioides difficile infections (CDIs), suffering from greater morbidity and mortality than the general population. Previous studies have proven the efficacy of oral vancomycin therapy in CDI, but there are no definitive guidelines to treat patients with IBD.…

Read More

The Outcomes of Emergency Admissions with Ulcerative Colitis between 2007 and 2017 in England.

The Outcomes of Emergency Admissions with Ulcerative Colitis between 2007 and 2017 in England. J Crohns Colitis. 2019 Nov 12;: Authors: King D, Rees J, Mytton J, Harvey P, Thomas T, Cooney R, Patel P, Trudgill N Abstract BACKGROUND AND AIMS: Patients with Ulcerative Colitis (UC) may present as emergencies and require rapid escalation of therapy. This study aimed to assess the mortality, colectomy and readmission risk during and following a first emergency admission with UC. METHODS: Using Hospital Episode Statistics, subjects aged between 18-60 years, coded with a first…

Read More

Autologous Exosome Transfer: A New Personalized Treatment Concept to Prevent Colitis in a Murine Model.

Autologous Exosome Transfer: A New Personalized Treatment Concept to Prevent Colitis in a Murine Model. J Crohns Colitis. 2019 Nov 09;: Authors: Yang C, Zhang M, Sung J, Wang L, Jung Y, Merlin D Abstract BACKGROUND AND AIMS: Epigenetic information delivered by intestinal exosomes can be useful for diagnosing intestinal diseases, such as ulcerative colitis, but the therapeutic effects of intestinal exosomes have not been fully exploited. We herein developed an autologous exosome therapy that could treat intestinal disease without any risk of inducing a systemic immunological reaction. METHODS: Intestinal…

Read More

ECCO Guidelines on Therapeutics in Crohn’s Disease: medical treatment.

ECCO Guidelines on Therapeutics in Crohn’s Disease: medical treatment. J Crohns Colitis. 2019 Nov 11;: Authors: Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J,…

Read More
<< Go Back